Join to view full profile
MadisonMadison, WI 53792
Dr. Paplomata is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2011 - 2014
Texas Health Resources (Dallas)Residency, Internal Medicine, 2008 - 2011
Istanbul University FomClass of 2001
Certifications & Licensure
NM State Medical License 2025 - 2029
TX State Medical License 2024 - 2028
IN State Medical License 2025 - 2027
KS State Medical License 2025 - 2027
KY State Medical License 2024 - 2027
MN State Medical License 2025 - 2027
NC State Medical License 2026 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2016
- CMS Meaningful Use Stage 1 Certification HealtheLife and PowerChart, Cerner Corporation, 2016
- CMS Meaningful Use Stage 1 Certification P2 Sentinel, Cerner Corporation, 2016
Clinical Trials
Publications & Presentations
PubMed
- 2 citationsCorrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metas...G Curigliano, V Mueller, V Borges, E Hamilton, S Hurvitz
Annals of Oncology. 2023-07-01 - 22 citationsCancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies:State-of-the-Art Review.Susmita Parashar, Nausheen Akhter, Elisavet Paplomata, Islam Y Elgendy, Deepa Upadhyaya
JACC. Cardiooncology. 2023-04-01 - 159 citationsTucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Bra...Nancy U Lin, Rashmi K Murthy, Vandana Abramson, Carey Anders, Thomas Bachelot
JAMA Oncology. 2023-02-01
Journal Articles
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerRita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology
Authored Content
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerJuly 2020
Press Mentions
At the Intersection of Breast and Gynecologic Cancers: Dr. Elisavet PaplomataMay 14th, 2020
mTOR Biology and the Growing Role for mTOR Inhibitors in the Management of Breast CancerMarch 27th, 2015
Professional Memberships
- Member
Other Languages
- Greek, Turkish, French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: